
    
      a prospective study included patients who were referred to our outpatient clinics in
      Farwanyia hospital, Kuwait during the period between July 2019 and January 2020, having
      symptomatic epiphora associated with severe acquired lower punctal stenosis. Patients were
      treated with topical 0.05% CsA on twice daily dose with topical preservative free artificial
      tears Q.I. D. Patients were followed up monthly for at least 3 months by epiphora grading,
      Fluorescein dye disappearance test (FDT) and evaluating the patient satisfaction
    
  